A case of dystrophic epidermolysis bullosa improved with etanercept for concomitant psoriatic arthritis.
Epidermolysis bullosa is a group of inherited, chronic, non-inflammatory skin disorders, and dystrophic epidermolysis bullosa (DEB) is one of the most severe variants. The role of tumour necrosis factor alpha (TNFalpha) has not been reported in the pathogenesis of DEB. A DEB case is reported that appears to have responded well to the TNFalpha inhibitor etanercept given for the treatment of concomitant psoriatic arthritis. A progressive improvement in DEB was apparent over the first 3 months of treatment and persistent good control of DEB was noted over 3 years of therapy. A correlation between DEB improvement and etanercept has not been made, but the case may provide insight into the causal mechanisms of DEB.
Gubinelli
Emanuela
E
Istituto Dermopatico dell'Immacolata (IDI) IRCCS, Via dei Monti de Creta 104, 00167 Rome, Italy. e.gubinelli@idi.it
Angelo
Corrado
C
Pacifico
Valeria
V
D000328:Adult; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy; D016108:Epidermolysis Bullosa Dystrophica / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept